Cross-platform multi-laboratory screening identifies HUWE1, USP33 and USP20 as negative-regulators of autophagy or mitophagy with relevance to neurodegeneration
This cross-platform, multi-laboratory study establishes a framework for identifying and validating regulators of autophagy and mitophagy and provides a route which enables a comprehensive reassessment of the current target literature in this field.
Abstract
Autophagy and mitophagy are essential cellular processes implicated in neurodegenerative diseases, yet few tractable targets have been robustly validated for therapeutic modulation of these pathways. In an industry-academia consortium we carried out an extensive literature review and expert curation, leading to selection of 29 genes previously reported to enhance autophagy upon genetic or pharmacological modulation. These genes were classified based on whether downregulation or overexpression induced autophagic activity. Using siRNA knockdown, small-molecule modulators, and transient transfection approaches, we systematically screened these targets in parallel across HeLa and HEK-293 cell lines using high- and low-content phenotypic imaging. Promising candidates were further evaluated in induced pluripotent stem cell (iPSC)-derived neurons and in Drosophila models. Three targets emerged as top candidates: HUWE1 downregulation consistently enhanced autophagy and aggregate clearance, while USP33 downregulation promoted mitophagy. We also identified USP20, a close homologue of USP33, as an inhibitor of mitophagy, a role not previously assigned to this protein. These effects on autophagy/mitophagy were corroborated in Drosophila, highlighting their potential functional relevance across species. This cross-platform, multi-laboratory study establishes a framework for identifying and validating regulators of autophagy and mitophagy and provides a route which enables a comprehensive reassessment of the current target literature in this field. The validation of HUWE1, USP20, and USP33 as candidate therapeutic targets offers new opportunities for intervention in neurodegenerative diseases.
BACKGROUND
Ovarian cancer (OC) is a lethal malignancy with limited therapies. The natural compound dihydrotanshinone I (DHT) exhibits broad antitumor activity, yet its precise molecular targets and mechanistic interplay with oncogenic lncRNAs in OC remain largely unexplored.
PURPOSE
This study aimed to investigate th...
Elevated α-synuclein, encoded by SNCA, is central to Parkinson’s disease pathology, and lowering
SNCA expression is an actively pursued therapeutic strategy. Genes whose inhibition reduces SNCA
without broadly disturbing the transcriptome would be useful starting points for experimental follow-up.
We analyzed the Arc I...
Aditya Desai, Daniel Plymire· American Journal of Student...· 0 citations
Abstract Ferroptosis is a regulated form of cell death driven by iron‐dependent lipid peroxidation and has emerged as a promising therapeutic target in nonsmall cell lung cancer (NSCLC). However, the specific mechanisms by which nonsmall cell lung cancer cells evade ferroptosis remain to be further elucidated. We condu...
Xin Fan, Yu-Biao Lin, Zhi-Gao Zhen et al.· Journal of cell communicatio...· 0 citations
This study identifies a novel ‘PD-L1–ER stress–pyruvate–macrophage senescence’ axis as a key mechanism underlying primary resistance to ICB and proposes that targeting the PDK4/GLS-dependent pyruvate surge offers a promising therapeutic strategy to sensitize tumors to anti-PD-1 immunotherapy.
Wen-Xin Lian, Hui Yang, Yu-Qi Zhang et al.· Journal for ImmunoTherapy of...· 0 citations
A scalable, semi-automated, and physiologically relevant hiPSC-derived macrophage model, rigorously characterised through deep comparative multi-omics is established and how genetic perturbations alter pro- and anti-inflammatory transcriptional signatures and significantly impact functional phenotypes are showcased.
Pancreatic ductal adenocarcinoma (PDAC) is dependent on mutant KRAS and elevated autophagy for growth. Previously, we and others demonstrated that pharmacological inhibition of the KRAS ERK-MAPK pathway caused increased autophagic flux. Targeting this increased autophagic flux with inhibitors that block autophagic pr...
Seamus E. Degan, Mallory K. Roach, Jonathan M. DeLiberty et al.· Cancer Research· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.